Citi upgraded Merck shares to buy and raised its price target to $130. The firm believes that Merck's drug pipeline is underappreciated by the market. Originally published at CNBC
Trending
- Wild Stories Of Adults With No Hygiene Or Life Skills
- What the data actually shows
- Apate sends AI agents undercover to get scammed so they can gather fraud intelligence
- Is It Time to Rebalance Your Portfolio?
- Trump’s Response To Protester Being Attacked At His Rally Sparks Outrage
- 7 Things You Should Never Leave in a Rental Car
- How These Friends Opened a Color Me Mine Pottery Franchise
- LeaseCommand – Company Profile – AllBusiness.com
Add A Comment